RECRUITING

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Official Title

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor

Quick Facts

Study Start:2025-08
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07075471

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of TGCT according to medical records
  2. 2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
  3. 3. Has provided informed consent and medical records release
  1. 1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
  2. 2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
  3. 3. Participant is active in an interventional clinical trial of vimseltinib

Contacts and Locations

Study Contact

Clinical Team
CONTACT
785-830-2100
clinicaltrials@deciphera.com

Principal Investigator

Clinical Team
STUDY_DIRECTOR
Deciphera Pharmaceuticals, LLC

Study Locations (Sites)

Synexus Clinical Research, US INC
Wilmington, North Carolina, 28401
United States

Collaborators and Investigators

Sponsor: Deciphera Pharmaceuticals, LLC

  • Clinical Team, STUDY_DIRECTOR, Deciphera Pharmaceuticals, LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08
Study Completion Date2027-09

Study Record Updates

Study Start Date2025-08
Study Completion Date2027-09

Terms related to this study

Additional Relevant MeSH Terms

  • Tenosynovial Giant Cell Tumor